Shares of Indian pharmaceutical companies slid 2% on Wednesday after U.S. President Donald Trump said he intends to impose ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy West Pharmaceutical Services? Access our full analysis ...

William Blair writes that West Pharmaceutical stock currently trades at 52.8 times the midpoint of the company's 2025 adjusted EPS guidance. "Generally speaking, we expect the stock to track to ...

Does any of this change the premise for buying Recursion Pharmaceuticals stock? Not really. The company's technology is promising. However, its experimental drugs are also still in the early ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

Robert W. Baird dropped their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Finally ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period.

William Blair writes that West Pharmaceutical stock currently trades at 52.8 times the midpoint of the company's 2025 adjusted EPS guidance. "Generally speaking, we expect the stock to track to ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.